Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM

Clinical endocrinology1 Mar 1994Cited by 39 (Europe PMC)

PMID8187308DOI10.1111/j.1365-2265.1994.tb03941.xPepBankPUB-08187308

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with TSH-secreting adenomas, lanreotide acutely reduced TSH to the same extent as octreotide.
In plain wordsIn patients with TSH-secreting adenomas, lanreotide reduced TSH to the same extent as octreotide.
Peptide
Lanreotide
Outcome
Direction not reportedAcute TSH suppression
Study
n = 4
Comparator
150 micrograms octreotide
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
500 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
500 micrograms lanreotide acutely reduced plasma TSH and fAS levels to the same extent as 150 micrograms octreotide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the first step of the study the patients received in a random order, vehicle, 150 micrograms octreotide and 500 micrograms lanreotide as a single s.c. injection.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730801
02HumanRandomized controlled trialEfficacy outcome
In patients with TSH-secreting adenomas, lanreotide acutely reduced free alpha subunit levels to the same extent as octreotide.
In plain wordsIn patients with TSH-secreting adenomas, lanreotide reduced free alpha subunit levels to the same extent as octreotide.
Peptide
Lanreotide
Outcome
Direction not reportedAcute free alpha subunit suppression
Study
n = 4
Comparator
150 micrograms octreotide
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
500 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
500 micrograms lanreotide acutely reduced plasma TSH and fAS levels to the same extent as 150 micrograms octreotide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the first step of the study the patients received in a random order, vehicle, 150 micrograms octreotide and 500 micrograms lanreotide as a single s.c. injection.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730802
03HumanNon-randomized trialPharmacokinetics
In adenoma patients, lanreotide concentrations were 7.8 +/- 0.6 micrograms/l at two hours, 1.8 +/- 0.2 on day 2, and 1.1 +/- 0.3 on day 14.
In plain wordsIn adenoma patients, lanreotide concentrations declined after the single injection through day 14.
Peptide
Lanreotide
Outcome
Not applicableLanreotide plasma concentrations
Study
n = 4
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30 mg · intramuscularAs given in this study (human).
Measurements
Plasma lanreotide concentration
7.8 micrograms/l
2 h after 30 mg SR-L; reported as +/- 0.6
Plasma lanreotide concentration
1.8 microgram/l
day 2; reported as +/- 0.2
Plasma lanreotide concentration
1.1 microgram/l
day 14; reported as +/- 0.3
Source sentences
Summary
Two hours after a single i.m. injection of SR-L plasma lanreotide levels reached 7.8 +/- 0.6 micrograms/l and then progressively decreased, being 1.8 +/- 0.2 microgram/l on day 2 and 1.1 +/- 0.3 microgram/l on day 14 after the injection.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second part of the study, after a basal blood sample (0800 h), each patient received 30 mg lanreotide as an i.m. injection of SR-L.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730803
04HumanNon-randomized trialEfficacy outcome
In adenoma patients, TSH fell from 4.4 +/- 1.2 mlU/l to 2.5 +/- 0.8 within 2 hours and 0.8 +/- 0.2 on day 2.
In plain wordsIn patients with TSH-secreting adenomas, TSH decreased within 2 hours and declined further by day 2 after lanreotide.
Peptide
Lanreotide
Outcome
DecreaseTSH after single slow-release injection
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg · intramuscularAs given in this study (human).
Measurements
Plasma TSH
4.4 mlU/l
basal; mean +/- SEM 1.2
Plasma TSH
2.5 mlU/l
within 2 hours of SR-L; reported as +/- 0.8
Plasma TSH
0.8 ml/Ul
day 2 after injection; reported as +/- 0.2
Source sentences
Summary
Plasma TSH level decreased from basal value (mean +/- SEM 4.4 +/- 1.2 mlU/l) within 2 hours (2.5 +/- 0.8 mlU/l) and further declined to 0.8 +/- 0.2 ml/Ul on day 2 following the injection.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second part of the study, after a basal blood sample (0800 h), each patient received 30 mg lanreotide as an i.m. injection of SR-L.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730804
05HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, TSH remained reduced for 6-15 days after lanreotide injection.
In plain wordsIn patients with TSH-secreting adenomas, TSH remained reduced for 6-15 days after lanreotide injection.
Peptide
Lanreotide
Outcome
DecreaseDuration of TSH suppression
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg · intramuscularAs given in this study (human).
Measurements
Duration of reduced plasma TSH
6 to 15 days
depending on the patient
Source sentences
Summary
Depending on the patient, plasma TSH levels were reduced for a period of 6-15 days.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second part of the study, after a basal blood sample (0800 h), each patient received 30 mg lanreotide as an i.m. injection of SR-L.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730805
06HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, free T4 normalized on day 2 after lanreotide and remained normal for 9-20 days.
In plain wordsIn patients with TSH-secreting adenomas, free T4 normalized on day 2 after lanreotide and remained normal for 9-20 days.
Peptide
Lanreotide
Outcome
Direction not reportedFree T4 normalization
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg · intramuscularAs given in this study (human).
Measurements
Duration within normal range
9 to 20 days
after normalization on day 2 (fT4 and fT3 reported together)
Source sentences
Summary
Plasma fT4, fT3 levels were normalized on day 2 and remained in the normal range for a period of time of 9-20 days.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second part of the study, after a basal blood sample (0800 h), each patient received 30 mg lanreotide as an i.m. injection of SR-L.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730806
07HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, free T3 normalized on day 2 after lanreotide and remained normal for 9-20 days.
In plain wordsIn patients with TSH-secreting adenomas, free T3 normalized on day 2 after lanreotide and remained normal for 9-20 days.
Peptide
Lanreotide
Outcome
Direction not reportedFree T3 normalization
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg · intramuscularAs given in this study (human).
Measurements
Duration within normal range
9 to 20 days
after normalization on day 2 (fT4 and fT3 reported together)
Source sentences
Summary
Plasma fT4, fT3 levels were normalized on day 2 and remained in the normal range for a period of time of 9-20 days.
2 context sentences(design, population, supporting numbers)
Summary · context
In the second part of the study, after a basal blood sample (0800 h), each patient received 30 mg lanreotide as an i.m. injection of SR-L.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730807
08HumanNon-randomized trialSafety outcome
In patients with TSH-secreting adenomas, abdominal cramps appeared together with diarrhoea during long-term lanreotide treatment, leading to interruption of treatment in one patient.
In plain wordsIn patients with TSH-secreting adenomas, abdominal cramps appeared during long-term lanreotide treatment, and one patient interrupted treatment.
Peptide
Lanreotide
Outcome
Not applicableAbdominal cramps
Study
n = 4
Outcome group
Gastrointestinal adverse events · Endocrine and hormones
Studied dose
one SR-L injection twice a month (three times a month in one case); per-injection dose not stated for this phase · intramuscular · 3-6 monthsAs given in this study (human).
Measurements
Patients with treatment interruption
1 patients
4 patients; abdominal cramps and diarrhoea
Source sentences
Summary
During long-term treatment, abdominal cramps and diarrhoea appeared, leading to interruption of the treatment in one patient.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730808
09HumanNon-randomized trialSafety outcome
In patients with TSH-secreting adenomas, diarrhoea appeared together with abdominal cramps during long-term lanreotide treatment, leading to interruption of treatment in one patient.
In plain wordsIn patients with TSH-secreting adenomas, diarrhoea appeared during long-term lanreotide treatment, and one patient interrupted treatment.
Peptide
Lanreotide
Outcome
Not applicableDiarrhoea
Study
n = 4
Outcome group
Gastrointestinal adverse events · Endocrine and hormones
Studied dose
one SR-L injection twice a month (three times a month in one case); per-injection dose not stated for this phase · intramuscular · 3-6 monthsAs given in this study (human).
Measurements
Patients with treatment interruption
1 patients
4 patients; abdominal cramps and diarrhoea
Source sentences
Summary
During long-term treatment, abdominal cramps and diarrhoea appeared, leading to interruption of the treatment in one patient.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730809
10HumanNon-randomized trialSafety outcome
In patients with TSH-secreting adenomas, abdominal cramps and diarrhoea led to lanreotide treatment interruption in one patient.
In plain wordsIn patients with TSH-secreting adenomas, abdominal cramps and diarrhoea led to lanreotide treatment interruption in one patient.
Peptide
Lanreotide
Outcome
Not applicableTreatment interruption
Study
n = 4
Outcome group
Adverse events · Endocrine and hormones
Studied dose
30 mg twice or three times a month · intramuscular · 3-6 monthsAs given in this study (human).
Source sentences
Summary
During long-term treatment, abdominal cramps and diarrhoea appeared, leading to interruption of the treatment in one patient.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730810
11HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, TSH progressively decreased during long-term lanreotide treatment.
In plain wordsIn patients with TSH-secreting adenomas, TSH progressively decreased during long-term lanreotide treatment.
Peptide
Lanreotide
Outcome
DecreaseLong-term TSH
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg twice or three times a month · intramuscular · 3-6 monthsAs given in this study (human).
Source sentences
Summary
Plasma TSH and thyroid hormone levels progressively decreased during the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730812
12HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, thyroid hormone levels progressively decreased during long-term lanreotide treatment.
In plain wordsIn patients with TSH-secreting adenomas, thyroid hormone levels progressively decreased during long-term lanreotide treatment.
Peptide
Lanreotide
Outcome
DecreaseLong-term thyroid hormones
Study
n = 4
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
30 mg twice or three times a month · intramuscular · 3-6 monthsAs given in this study (human).
Source sentences
Summary
Plasma TSH and thyroid hormone levels progressively decreased during the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730813
13HumanNon-randomized trialEfficacy outcome
In patients with TSH-secreting adenomas, adenoma volume did not change after 3-6 months of lanreotide therapy.
In plain wordsIn patients with TSH-secreting adenomas, adenoma volume did not change after 3-6 months of lanreotide therapy.
Peptide
Lanreotide
Outcome
No significant changeAdenoma volume
Study
n = 4
Outcome group
Tumor growth · Cancer
Studied dose
30 mg twice or three times a month · intramuscular · 3-6 monthsAs given in this study (human).
Source sentences
Summary
No change in adenoma volume was observed after 3-6 months of therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730814
14HumanNon-randomized trialSafety outcome
Lanreotide was well tolerated in the other three patients with TSH-secreting adenomas.
In plain wordsLanreotide was well tolerated in the other three patients with TSH-secreting adenomas.
Peptide
Lanreotide
Outcome
Not applicableTolerability
Study
n = 3
Outcome group
Adverse events · Endocrine and hormones
Studied dose
30 mg twice or three times a month · intramuscular · 3-6 monthsAs given in this study (human).
Source sentences
Summary
The treatment was well tolerated in the other three patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients then received one SR-L injection twice or in one case three times a month for 3-6 months.
Summary · context
Four patients with hyperthyroidism linked to a TSH-secreting pituitary adenoma found on pituitary magnetic resonance imaging (MRI) and subsequently proved by immunohistochemistry were studied.
Report a problemFND-0818730811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.